Infusion-related events during natalizumab: no need for post-infusion monitoring

F. C. Loonstra; J. A. van Rossum; Z. L. E. van Kempen; T. Rispens; B. M. J. Uitdehaag; J. Killestein

doi:https://doi.org/10.1177/1352458519860415

Infusion-related events during natalizumab: no need for post-infusion monitoring

F. C. Loonstra, J. A. van Rossum, Z. L. E. van Kempen, T. Rispens, B. M. J. Uitdehaag, J. Killestein

Research output: Contribution to journal › Meeting Abstract › Academic

1 Citation (Scopus)

Abstract

This retrospective cohort study assessed the timing of infusion-related adverse events (IAEs) during natalizumab (NTZ) administration in well-documented relapsing-remitting multiple sclerosis (RRMS) patients who had received NTZ infusions in our centre between 2006 and 2018. In 225 RRMS patients (14,174 NTZ infusions), 276 IAEs (1.95%) occurred in 60 patients. All documented severe IAE occurred during infusion. Of the 19 moderate adverse events, 17 were during infusion. None of the reactions that occurred after the infusion required intervention. These results suggest that post-infusion monitoring is not necessary in patients who do not have an adverse event during infusion.

Original language	English
Pages (from-to)	26-26
Number of pages	4
Journal	MULTIPLE SCLEROSIS JOURNAL
Volume	25
Issue number	12
Early online date	25 Jun 2019
DOIs	https://doi.org/10.1177/1352458519860415
Publication status	Published - Sept 2019

Keywords

Multiple sclerosis
adverse-events
antibodies
infusion-reactions
monitoring
natalizumab

Access to Document

https://doi.org/10.1177/1352458519860415

Cite this

@article{4fc75ea008c742feadcceb9363665f4c,

title = "Infusion-related events during natalizumab: no need for post-infusion monitoring",

abstract = "This retrospective cohort study assessed the timing of infusion-related adverse events (IAEs) during natalizumab (NTZ) administration in well-documented relapsing-remitting multiple sclerosis (RRMS) patients who had received NTZ infusions in our centre between 2006 and 2018. In 225 RRMS patients (14,174 NTZ infusions), 276 IAEs (1.95%) occurred in 60 patients. All documented severe IAE occurred during infusion. Of the 19 moderate adverse events, 17 were during infusion. None of the reactions that occurred after the infusion required intervention. These results suggest that post-infusion monitoring is not necessary in patients who do not have an adverse event during infusion.",

keywords = "Multiple sclerosis, adverse-events, antibodies, infusion-reactions, monitoring, natalizumab",

author = "Loonstra, {F. C.} and {van Rossum}, {J. A.} and {van Kempen}, {Z. L. E.} and T. Rispens and Uitdehaag, {B. M. J.} and J. Killestein",

year = "2019",

month = sep,

doi = "https://doi.org/10.1177/1352458519860415",

language = "English",

volume = "25",

pages = "26--26",

journal = "MULTIPLE SCLEROSIS JOURNAL",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "12",

}

TY - JOUR

T1 - Infusion-related events during natalizumab: no need for post-infusion monitoring

AU - Loonstra, F. C.

AU - van Rossum, J. A.

AU - van Kempen, Z. L. E.

AU - Rispens, T.

AU - Uitdehaag, B. M. J.

AU - Killestein, J.

PY - 2019/9

Y1 - 2019/9

N2 - This retrospective cohort study assessed the timing of infusion-related adverse events (IAEs) during natalizumab (NTZ) administration in well-documented relapsing-remitting multiple sclerosis (RRMS) patients who had received NTZ infusions in our centre between 2006 and 2018. In 225 RRMS patients (14,174 NTZ infusions), 276 IAEs (1.95%) occurred in 60 patients. All documented severe IAE occurred during infusion. Of the 19 moderate adverse events, 17 were during infusion. None of the reactions that occurred after the infusion required intervention. These results suggest that post-infusion monitoring is not necessary in patients who do not have an adverse event during infusion.

AB - This retrospective cohort study assessed the timing of infusion-related adverse events (IAEs) during natalizumab (NTZ) administration in well-documented relapsing-remitting multiple sclerosis (RRMS) patients who had received NTZ infusions in our centre between 2006 and 2018. In 225 RRMS patients (14,174 NTZ infusions), 276 IAEs (1.95%) occurred in 60 patients. All documented severe IAE occurred during infusion. Of the 19 moderate adverse events, 17 were during infusion. None of the reactions that occurred after the infusion required intervention. These results suggest that post-infusion monitoring is not necessary in patients who do not have an adverse event during infusion.

KW - Multiple sclerosis

KW - adverse-events

KW - antibodies

KW - infusion-reactions

KW - monitoring

KW - natalizumab

UR - http://www.scopus.com/inward/record.url?scp=85068325183&partnerID=8YFLogxK

U2 - https://doi.org/10.1177/1352458519860415

DO - https://doi.org/10.1177/1352458519860415

M3 - Meeting Abstract

C2 - 31237826

SN - 1352-4585

VL - 25

SP - 26

EP - 26

JO - MULTIPLE SCLEROSIS JOURNAL

JF - MULTIPLE SCLEROSIS JOURNAL

IS - 12

ER -

Infusion-related events during natalizumab: no need for post-infusion monitoring

Abstract

Keywords

Access to Document

Other files and links

Cite this